Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fish Oil→

Fish Oil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8016-13-5
Molecular formula
Not available
Molecular weight
Not available
Drug class
Omega-3 fatty acid-rich triglyceride mixtureParenteral lipid emulsion component
Mechanism of action
The fish-oil triglyceride mixture provides calories and essential fatty acids. Fatty acids serve as substrates for energy production and contribute to membrane structure and bioactive-molecule synthesis.
Indications / reported uses
  • Omegaven-specific labelled use: source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)

Sources: DailyMed — Omegaven fish oil injectable emulsion prescribing information · US FDA — Omegaven approved labelled indication · US FDA — Omegaven fish oil composition

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fish Oil Environmental Risk Assessment (ERA) (the Fish Oil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.